Episode 180 - April 17, 2026

Episode 180 - April 17, 2026

From Biotech Hangout by Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more

April 17, 2026 · 54 min

About this episode

The episode discusses the current state of the biotech market, recent IPOs, and the impact of clinical data and AI tools in the industry.

On today’s episode, Chris Carabedian, Paul Matteis, Tess Cameron, and special guest Adam Feuerstein kick off with a discussion of the public markets, highlighting the XBI’s post‑pandemic highs, Kailera’s IPO pricing and more than $625 million raised, the opening of the IPO window with multiple filings, and increasing generalist interest in the biotech sector. The group also discusses Obsidian Therapeutics going public following a reverse merger with Galera, alongside a $350 million PIPE. The conversation shifts to the rise of clinical trial prediction markets and the growing role of AI tools in the life sciences industry. Next, the co‑hosts highlight another acquisition by Lilly, with their $300 million purchase of Crossbridge Bio. In Regulatory news, the group overview the FDA approval of Travere Therapeutics’ kidney disease drug for FSGS and the broader implications for the renal space. On the data front, the group mentions Allogene’s CAR‑T data and the mixed stock reaction, along with Revolution Medicines’ positive Phase 3 data in pancreatic cancer. Spyre’s positive Phase 2 data in ulcerative colitis is also covered. The episode concludes with a discussion on how clinical data…

People in this episode

Guests: Chris Carabedian, Paul Matteis, Tess Cameron, Adam Feuerstein

Topics covered

  • public markets
  • biotech sector
  • clinical trials
  • AI in life sciences
  • FDA approvals
  • market dynamics

Keywords

  • biotech
  • IPO
  • clinical trials
  • FDA approval
  • AI tools
  • market dynamics
  • kidney disease
  • CAR-T data
  • Phase 3 data

Mentioned in this episode

Organizations: XBI, Kailera, Obsidian Therapeutics, Galera, Lilly, Crossbridge Bio, FDA, Travere Therapeutics, Allogene, Revolution Medicines

More episodes of Biotech Hangout

Explore listener stats, chart rankings, contacts and more on the Biotech Hangout podcast page.